Key takeaway
Among 1,725 adults with sarcopenia in NHANES, those in the highest quartile of the monocyte-to-lymphocyte ratio (MLR) had a higher risk of all-cause death (HR = 1.619 [1.290-2.032]) than the lowest quartile. This is an observational link in one US survey, and blood ratios measured once cannot show that inflammation causes the deaths.
Study design
Research article
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Inflammation may contribute to sarcopenia, the loss of muscle mass and strength. The authors tested whether ratios calculated from a routine complete blood count (CBC) relate to having sarcopenia and to later death.
Who and how
Analysis of the 1999-2006 National Health and Nutrition Examination Survey (NHANES) with deaths ascertained through the National Death Index up to December 31, 2019. The cohort had 12,689 individuals, of whom 1,725 had sarcopenia. Indicators were NLR, dNLR, MLR, NMLR, SIRI and SII. Models adjusted for confounders, and random survival forests (RSF) compared predictive power.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Higher NLR, dNLR, NMLR, SIRI and SII were associated with higher prevalence of sarcopenia after adjustment.
- 2Among people with sarcopenia, 782 died of any cause and 195 of cardiovascular causes. Highest vs. lowest quartile for all-cause mortality: NLR HR = 1.336 [1.095-1.631], dNLR 1.274 [1.046-1.550], MLR 1.619 [1.290-2.032], NMLR 1.390 [1.132-1.707] and SIRI 1.501 [1.210-1.862].
- 3For cardiovascular mortality, MLR (HR = 1.874 [1.169-3.003]) and SIRI (HR = 1.838 [1.175-2.878]) were similarly associated.
- 4In the RSF analysis MLR had the highest predictive power for both all-cause and cardiovascular mortality.
Limits & uncertainty
- 1Inflammatory ratios were taken from blood counts and may reflect infection, illness or medications rather than chronic inflammation alone.
- 2Observational data cannot show cause, and the abstract does not say how sarcopenia was defined or which confounders were adjusted.
- 3Cardiovascular death numbers (195) are small, so those intervals are wide.
- 4This reading is based on the abstract only.
What to take from it
A routine blood count may carry some prognostic information in people with sarcopenia, with MLR looking most informative in this dataset. It does not show that lowering these ratios improves survival. Any blood test results and what to do about them are for a clinician to interpret.
Reading your own data
These ratios come from lab blood tests, not from wearables. What you can track is muscle-related function such as grip strength, walking pace or weight and body composition on a consistent device, viewed as trends over months.
How to read this evidence
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
It has been proposed that inflammation plays a role in the development of sarcopenia. This study aimed to investigate the links of complete blood cell count (CBC) parameters and CBC-derived inflammatory indicators with sarcopenia and mortality.
Methods
Data pertaining to sarcopenia were extracted from the 1999-2006 National Health and Nutrition Examination Survey (NHANES), and mortality events were ascertained through the National Death Index up to December 31, 2019. The CBC-derived inflammatory indicators assessed in this study included the neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), neutrophil-monocyte to lymphocyte ratio (NMLR), systemic inflammatory response index (SIRI), and systemic immune-inflammation index (SII). The prognostic significance of these CBC-derived inflammatory indicators was evaluated using the random survival forests (RSF) analysis.
Results
The study encompassed a cohort of 12,689 individuals, among whom 1,725 were diagnosed with sarcopenia. Among individuals with sarcopenia, 782 experienced all-cause mortality, and 195 succumbed to cardiovascular causes. Following adjustment for confounding variables, it was observed that elevated levels of NLR, dNLR, NMLR, SIRI, and SII were associated with an increased prevalence of sarcopenia. Among participants with sarcopenia, those in the highest quartile of NLR (HR = 1.336 [1.095-1.631]), dNLR (HR = 1.274 [1.046-1.550]), MLR (HR = 1.619 [1.290-2.032]), NMLR (HR = 1.390 [1.132-1.707]), and SIRI (HR = 1.501 [1.210-1.862]) exhibited an elevated risk of all-cause mortality compared to those in the lowest quartile of these inflammation-derived indicators. These associations were similarly observed in cardiovascular mortality (HR = 1.874 [1.169-3.003] for MLR, HR = 1.838 [1.175-2.878] for SIRI). The RSF analysis indicated that MLR exhibited the highest predictive power for both all-cause and cardiovascular mortality among individuals with sarcopenia.
Conclusions
Our findings underscore the association between CBC-derived inflammatory indicators and mortality in adults with sarcopenia. Of note, MLR emerged as the most robust predictor of all-cause and cardiovascular mortality in this population.
Sources & attribution
Associations of CBC-Derived inflammatory indicators with sarcopenia and mortality in adults: evidence from Nhanes 1999 ∼ 2006.
Guo B, Liu X, Si Q, Zhang D, Li M, Li X, Zhao Y, Hu F, Zhang M, Liu Y, Hu D.
BMC geriatrics · 2024-05-16
DOI: 10.1186/s12877-024-05012-2 ↗PubMed · 38755603 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

